Analysts expect MEI Pharma Inc (NASDAQ:MEIP) to report ($0.20) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for MEI Pharma’s earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.38). MEI Pharma posted earnings per share of ($0.13) during the same quarter last year, which indicates a negative year-over-year growth rate of 53.8%. The firm is expected to announce its next quarterly earnings results on Thursday, August 29th.
On average, analysts expect that MEI Pharma will report full year earnings of ($0.67) per share for the current financial year, with EPS estimates ranging from ($0.98) to ($0.41). For the next financial year, analysts expect that the business will post earnings of ($0.79) per share, with EPS estimates ranging from ($1.08) to ($0.51). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that follow MEI Pharma.
A number of analysts have recently issued reports on MEIP shares. BTIG Research started coverage on shares of MEI Pharma in a research note on Tuesday, February 12th. They set a “buy” rating on the stock. Oppenheimer reiterated a “buy” rating on shares of MEI Pharma in a research note on Tuesday, March 19th. Zacks Investment Research lowered shares of MEI Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Finally, HC Wainwright reissued a “buy” rating on shares of MEI Pharma in a report on Friday, May 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. MEI Pharma has an average rating of “Buy” and an average target price of $8.05.
Shares of MEIP traded down $0.03 during mid-day trading on Thursday, hitting $2.64. The company had a trading volume of 87,094 shares, compared to its average volume of 215,238. MEI Pharma has a 1-year low of $1.82 and a 1-year high of $5.14. The stock has a market capitalization of $192.48 million, a PE ratio of -3.57 and a beta of 1.95.
MEI Pharma Company Profile
MEI Pharma, Inc, a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Featured Article: Understanding Market Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.